These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26524347)

  • 1. Triphenylethanamine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors: Discovery of N-[(1R)-1-(3-Cyclopropoxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide (BMS-795311).
    Qiao JX; Wang TC; Adam LP; Chen AY; Taylor DS; Yang RZ; Zhuang S; Sleph PG; Li JP; Li D; Yin X; Chang M; Chen XQ; Shen H; Li J; Smith D; Wu DR; Leith L; Harikrishnan LS; Kamau MG; Miller MM; Bilder D; Rampulla R; Li YX; Xu C; Lawrence RM; Poss MA; Levesque P; Gordon DA; Huang CS; Finlay HJ; Wexler RR; Salvati ME
    J Med Chem; 2015 Nov; 58(22):9010-26. PubMed ID: 26524347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility.
    Kalgutkar AS; Frederick KS; Hatch HL; Ambler CM; Perry DA; Garigipati RS; Chang GC; Lefker BA; Clark RW; Morehouse LA; Francone O; Hu X
    Xenobiotica; 2014 Jul; 44(7):591-605. PubMed ID: 24380613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent cholesteryl ester transfer protein inhibitors of reduced lipophilicity: 1,1'-spiro-substituted hexahydrofuroquinoline derivatives.
    Trieselmann T; Wagner H; Fuchs K; Hamprecht D; Berta D; Cremonesi P; Streicher R; Luippold G; Volz A; Markert M; Nar H
    J Med Chem; 2014 Nov; 57(21):8766-76. PubMed ID: 25265559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diphenylpyridylethanamine (DPPE) derivatives as cholesteryl ester transfer protein (CETP) inhibitors.
    Harikrishnan LS; Finlay HJ; Qiao JX; Kamau MG; Jiang J; Wang TC; Li J; Cooper CB; Poss MA; Adam LP; Taylor DS; Chen AY; Yin X; Sleph PG; Yang RZ; Sitkoff DF; Galella MA; Nirschl DS; Van Kirk K; Miller AV; Huang CS; Chang M; Chen XQ; Salvati ME; Wexler RR; Lawrence RM
    J Med Chem; 2012 Jul; 55(13):6162-75. PubMed ID: 22650305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and biological evaluation of (2R,alphaS)-3,4-dihydro-2-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-5-[3-(trifluoromethoxy)-phenyl]-alpha-(trifluoromethyl)-1(2H)-quinolineethanol as potent and orally active cholesteryl ester transfer protein inhibitor.
    Kuo GH; Rano T; Pelton P; Demarest KT; Gibbs AC; Murray WV; Damiano BP; Connelly MA
    J Med Chem; 2009 Mar; 52(6):1768-72. PubMed ID: 19236017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure.
    Blasi E; Bamberger M; Knight D; Engwall M; Wolk R; Winter S; Betts A; John-Baptiste A; Keiser J
    J Cardiovasc Pharmacol; 2009 Jun; 53(6):507-16. PubMed ID: 19455053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport.
    Tchoua U; D'Souza W; Mukhamedova N; Blum D; Niesor E; Mizrahi J; Maugeais C; Sviridov D
    Cardiovasc Res; 2008 Mar; 77(4):732-9. PubMed ID: 18056760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a Lead Triphenylethanamine Cholesterol Ester Transfer Protein (CETP) Inhibitor.
    Finlay HJ; Jiang J; Rampulla R; Salvati ME; Qiao JX; Wang TC; Lawrence RM; Harikrishnan LS; Kamau MG; Taylor DS; Chen AYA; Yin X; Huang CS; Chang M; Chen XQ; Sleph PG; Xu C; Li J; Levesque P; Adam LP; Wexler RR
    ACS Med Chem Lett; 2019 Jun; 10(6):911-916. PubMed ID: 31223447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice.
    Hansen MK; McVey MJ; White RF; Legos JJ; Brusq JM; Grillot DA; Issandou M; Barone FC
    J Cardiovasc Pharmacol Ther; 2010 Jun; 15(2):196-202. PubMed ID: 20332533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels.
    Clerc RG; Stauffer A; Weibel F; Hainaut E; Perez A; Hoflack JC; Bénardeau A; Pflieger P; Garriz JM; Funder JW; Capponi AM; Niesor EJ
    J Hypertens; 2010 Aug; 28(8):1676-86. PubMed ID: 20498617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refocusing on use of cholesteryl ester transfer protein inhibitors.
    Kastelein JJ
    Am J Cardiol; 2007 Dec; 100(11 A):n47-52. PubMed ID: 18047853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDL metabolism and CETP inhibition.
    Barkowski RS; Frishman WH
    Cardiol Rev; 2008; 16(3):154-62. PubMed ID: 18414186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure.
    Cao G; Beyer TP; Zhang Y; Schmidt RJ; Chen YQ; Cockerham SL; Zimmerman KM; Karathanasis SK; Cannady EA; Fields T; Mantlo NB
    J Lipid Res; 2011 Dec; 52(12):2169-2176. PubMed ID: 21957197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors.
    Vergeer M; Stroes ES
    Am J Cardiol; 2009 Nov; 104(10 Suppl):32E-8E. PubMed ID: 19895942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
    Shinkai H
    Expert Opin Ther Pat; 2009 Sep; 19(9):1229-37. PubMed ID: 19663630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CETP inhibitor torcetrapib promotes reverse cholesterol transport in obese insulin-resistant CETP-ApoB100 transgenic mice.
    Briand F; Thieblemont Q; André A; Ouguerram K; Sulpice T
    Clin Transl Sci; 2011 Dec; 4(6):414-20. PubMed ID: 22212222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition.
    Hu X; Dietz JD; Xia C; Knight DR; Loging WT; Smith AH; Yuan H; Perry DA; Keiser J
    Endocrinology; 2009 May; 150(5):2211-9. PubMed ID: 19164467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
    Briand F; Thieblemont Q; Muzotte E; Burr N; Urbain I; Sulpice T; Johns DG
    Eur J Pharmacol; 2014 Oct; 740():135-43. PubMed ID: 25008069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing high-density lipoprotein cholesterol, inhibition of cholesteryl ester transfer protein, and heart disease risk reduction.
    Schaefer EJ; Asztalos BF
    Am J Cardiol; 2007 Dec; 100(11 A):n25-31. PubMed ID: 18047849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raising HDL with CETP inhibitor torcetrapib improves glucose homeostasis in dyslipidemic and insulin resistant hamsters.
    Briand F; Prunet-Marcassus B; Thieblemont Q; Costard C; Muzotte E; Sordello S; Sulpice T
    Atherosclerosis; 2014 Apr; 233(2):359-362. PubMed ID: 24530763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.